Apigenin for Neuroprotection

Research suggests that apigenin shows broad neuroprotective potential across multiple neurological conditions, with studies pointing to mechanisms including reduction of oxidative stress, suppression of neuroinflammation, inhibition of toxic protein aggregation, mitochondrial preservation, and modulation of key signaling pathways such as Nrf2, NF-κB, and JAK/STAT. The body of evidence consists primarily of laboratory cell studies, animal models, and narrative and systematic reviews, with a 2025 animal study finding that apigenin activated protein-clearance pathways to reduce alpha-synuclein accumulation in a Parkinson's disease model, and a 2024 study reporting protection of retinal ganglion cells through improvements in mitochondrial dynamics; multiple reviews spanning 2018 to 2025 consistently characterize apigenin as a promising candidate for slowing neurodegeneration in conditions such as Alzheimer's and Parkinson's disease. Findings are not uniformly positive, however, as a 2023 mixed-direction study in rats following mild traumatic brain injury found that while apigenin reduced biochemical markers of damage, it did not produce meaningful improvements in cognitive or behavioral outcomes within the study's short observation window, and one study noting apigenin's role in a traditional stroke remedy identified its effects as primarily anti-platelet rather than directly neuroprotective. Significant limitations apply across the literature, including the near-total absence of human clinical trials, known challenges with apigenin's bioavailability and stability, and the general difficulty of translating preclinical findings into confirmed therapeutic outcomes in people.